---

$71.23

N/A ( 0% ) 12.6K

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-01-16	Sale	-110135.00	Schundler Russell
2024-01-16	Sale	-93250.00	Kaseta Michael
2023-12-20	Sale	-261.00	Adair Jason
2023-12-18	Buy	279330.00	Manning Paul B
2023-12-18	Buy	139665.00	JEFFS ROGER
2023-12-18	Sale	-14887.00	Saggar Rajeev
2023-12-14	Buy	1117318.00	Caligan Partners LP
2023-12-05	Sale	-1718.00	Lippe Robert A
2023-12-05	Sale	-2343.00	Kaseta Michael
2023-12-05	Sale	-1875.00	Moomaw Scott